X0508 4 2025-07-21 0001635088 Roivant Sciences Ltd. ROIV 0001801917 Venker Eric C/O ROIVANT SCIENCES LTD. 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB UNITED KINGDOM true President & Immunovant CEO true Common Shares 2025-07-21 4 M 0 100000 3.85 A 1562223 D Common Shares 2025-07-21 4 S 0 100000 11.52 D 1462223 D Stock Option (Right to Buy) 3.85 2025-07-21 4 M 0 100000 0 D 2032-04-19 Common Stock 100000 8138897 D The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker 2025-07-23